Boston Biotech Reports Promising Interim Data
Source: Dr. Swayampakula Ramakanth  (8/7/24)
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note. More >

Analyst Says CA Pharma Underappreciated by Investors
Source: Patrick Trucchio  (7/23/24)
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. More >

Analyst's Target Price for Biotech Massively Higher Than Current Price
Source: Dr. Leland Gershell  (7/22/24)
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price. More >

Study Shows 93% Cough Suppression With Co.'s Drug
Source: Streetwise Reports  (7/18/24)
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market." More >

Could This Stock Be the Next Bellus Cough Treatment?
Source: Clive Maund  (7/17/24)
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy. More >

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride
Source: Dr. Raghuram Selvaraju  (7/15/24)
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Reports Strong FQ224 Results Driven
Source: Dr. Douglas Loe  (7/11/24)
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX). More >

Texas Biotech Announces Plans for Preclinical Obesity Studies
Source: Dr. Jonathan Aschoff  (7/8/24)
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note. More >

AI Health Stock Heading Higher Expert Says
Source: Clive Maund  (7/2/24)
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher. More >

California Biotech Reports Positive Phase 3 Results
Source: Ed Arce  (6/25/24)
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. More >

Clean Tech Subsidiary Finds Manufacturer for Wound Solution
Source: Streetwise Reports  (6/14/24)
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic. More >

Is This Pharma Co. the Next Eli Lilly?
Source: Streetwise Reports  (6/11/24)
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly. More >

Rare Disease Co. Presents Positive Phase 2 KP1077 Data
Source: Dr. Jonathan Aschoff  (6/6/24)
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note. More >

Pharma Co. Secures $650M Strategic Financing
Source: Edward Nash  (5/16/24)
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine. More >

New COPD Drug Slated for Approval Decision This June
Source: Streetwise Reports  (5/15/24)
Ahead of the upcoming PDUFA date, several analysts recommend the biopharma behind this treatment as a Buy. Read on to learn why. More >

Pharma Stock Focuses on Successful Ensifentrine Launch
Source: Dr. Thomas Shrader   (5/15/24)
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note. More >

Pharma Stock Nears FDA Approval
Source: Andrew Tsai  (5/14/24)
According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval. More >

Breakthrough COPD Treatment Awaits FDA Approval, Promising Major Market Impact
Source: Streetwise Reports  (5/8/24)
Verona Pharma is poised for a pivotal breakthrough with its drug candidate, ensifentrine, potentially transforming COPD treatment pending an upcoming FDA decision. Read on for more.

More >

Biotech Co. Positioned for Ensifentrine Approval, Analyst Says
Source: Andrew Tsai  (5/6/24)
According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval. More >

Pharma's Promising Path in COPD Treatment
Source: Streetwise Reports  (4/26/24)
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock. More >

PDUFA Date Coming Up for U.K. Biopharma
Source: Edward Nash  (4/22/24)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report. More >

Biopharma's New Drug for COPD Likely to be Approved
Source: Ram Selvaraju  (4/22/24)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report. More >

Analyst Says Pharma Co. Has No True Competitor
Source: Andrew Tsai  (4/19/24)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note. More >

LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff  (4/17/24)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note. More >

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out
Source: Streetwise Reports  (4/8/24)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high. More >